Solar Lumbar Interbody Fusion System

K231199 · Degen Medical · MAX · Jun 16, 2023 · Orthopedic

Device Facts

• Record ID: K231199
• Device Name: Solar Lumbar Interbody Fusion System
• Applicant: Degen Medical
• Product Code: MAX · Orthopedic
• Decision Date: Jun 16, 2023
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3080
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

Solar-S™ (Standalone, With Integrated Fixation) and Solar-A™ (Non-Standalone, With Integrated Fixation) The Solar-S™ (Standalone) and Solar-A™ (Non-Standalone) are lumbar interbody fusion devices intended for use in patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbosacral spine (L2-S1). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. In addition, these patients may have up to Grade 1 spondylolisthesis at the involved level(s). These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. Solar-A™ ALIF Spacers are to be filled with autograft bone and/or allogenic bone graft composed of cancellous and/or corticocancellous bone. Solar-S™ Used With Screws: When used with three (3) screws, interbody devices with a lordotic angle < 20° can be used as standalone interbody fusion devices at 1 or 2 contiguous levels. Hyperlordotic interbody devices (>20° lordosis) used with screws, must always be used with supplemental fixation, and may be used at 1 or 2 levels. Solar-A™: These devices are intended to be used with supplemental fixation systems that have been cleared for use in the lumbosacral spine (e.g., posterior pedicle screw and rod systems, anterior screw and rod systems). Hyperlordotic interbody devices (≥20° lordosis) must be used with at least anterior supplemental fixation. Solar-M™ ALIF Spacers (Without Integrated Fixation) Solar-M™ ALIF Spacers are lumbar interbody fusion devices indicated at one or more levels of the thoracic spine (T1-T12), thoracolumbar junction (T12-L1), or lumbosacral spine (L1-S1) as an adjunct to fusion in patients with the following indications: degenerative disc disease (DD), disc herniation (with myelopathy and/or radiculopathy), spondylolilsthesis, deformity (degenerative scoliosis or kyphosis), spinal stenosis, and failed previous fusion (pseudarthrosis). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have has at least six (6) months of non-operative treatment. Solar-M™ ALIF Spacers are to be filled with autograft bone and/or allogenic bone graft composed of cancellous and/or corticocancellous bone. These devices are intended to be used with supplemental fixation systems that have been cleared for use in the thoracolumbosacral spine (e.g., posterior pedicle screw and rod systems, anterior plate systems, anterior screw and rod systems). Hyperlordotic interbody devices (≥20° lordosis) must be used with at least anterior supplemental fixation.

Device Story

Solar™ Lumbar Interbody Fusion System; additively manufactured unalloyed titanium spacers; used in posterior/transforaminal lumbar fusion procedures. Configurations include standalone (Solar-S™), anterolateral (Solar-A™), and monolithic (Solar-M™). Solar-S™ and Solar-A™ feature integrated fixation via Titanium-6AL-4V ELI alloy screws. Spacers feature porous endplates to mitigate subsidence/expulsion and central aperture for bone graft. Used by surgeons in clinical settings to stabilize spinal segments; provides structural support for fusion; promotes patient recovery from degenerative conditions.

Clinical Evidence

Bench testing only. Performed static/dynamic compression and compression shear (ASTM F2077), subsidence (ASTM F2267), expulsion testing, and wear debris characterization (ASTM F1877).

Technological Characteristics

Additively manufactured unalloyed titanium (Puri-Ti™) spacers; integrated fixation screws (Titanium-6AL-4V ELI per ASTM F136); porous surface architecture; various dimensions; standalone and non-standalone configurations.

Indications for Use

Indicated for skeletally mature patients with degenerative disc disease (DDD), disc herniation, spondylolisthesis, deformity, spinal stenosis, or failed fusion requiring interbody fusion in the thoracic, thoracolumbar, or lumbosacral spine. Requires 6 months of non-operative treatment.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• Osseus Fusion Systems PISCES™-SA Standalone ALIF Interbody System (K213935)
• Globus Medical Inc. HEDRON™ Lumbar Spacers (K191391, K222270)
• Blackstone Medical Pillar SA PEEK Spacer System (K081849)
• Zimmer Spine InFix Anterior Lumbar System (K132790)
• DeGen Medical Impulse AM™ Interbody Fusion System (K210090, K223418)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: a symbol on the left and the FDA name and title on the right. The symbol on the left is a stylized representation of a human figure, while the text on the right reads "FDA U.S. FOOD & DRUG ADMINISTRATION" in blue letters.

June 16, 2023

DeGen Medical % Justin Gracyalny, MSE Regulatory Affairs Manager Secure BioMed Evaluations 7828 Hickory Flat Highway Suite 120 Woodstock. Georgia 30188

Re: K231199

Trade/Device Name: Solar™ Lumbar Interbody Fusion System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: MAX, OVD, PHM Dated: April 27, 2023 Received: April 27, 2023

Dear Mr. Gracyalny:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

{1}------------------------------------------------

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

Brent Showalter -S

Brent Showalter, Ph.D. Assistant Director DHT6B: Division of Spinal Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## Indications for Use

510(k) Number (if known) K231199

Device Name Solar™ Lumbar Interbody Fusion System

### Indications for Use (Describe)

Solar-S™ (Standalone, With Integrated Fixation) and Solar-ATM (Non-Standalone, With Integrated Fixation) The Solar-STM (Standalone) and Solar-A™ (Non-Standalone) are lumbar interbody fusion devices intended for use in patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbosacral spine (L2-S1). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. In addition, these patients may have up to Grade 1 spondylolisthesis at the involved level(s). These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. Solar-A™ ALIF Spacers are to be filled with autograft bone and/or allogenic bone graft composed of cancellous and/or corticocancellous bone.

### · Solar-STM Used With Screws:

When used with three (3) screws, interbody devices with a lordotic angle < 20° can be used as standalone interbody fusion devices at 1 or 2 contiguous levels.

Hyperlordotic interbody devices (>20° lordosis) used with screws, must always be used with supplemental fixation, and may be used at 1 or 2 levels.

#### · Solar-ATM:

These devices are intended to be used with supplemental fixation systems that have been cleared for use in the lumbosacral spine (e.g., posterior pedicle screw and rod systems, anterior screw and rod systems). Hyperlordotic interbody devices (≥20° lordosis) must be used with at least anterior supplemental fixation.

Solar-M™ ALIF Spacers (Without Integrated Fixation) Solar-M™ ALIF Spacers are lumbar interbody fusion devices indicated at one or more levels of the thoracic spine (T1-T12), thoracolumbar junction (T12-L1), or lumbosacral spine (L1-S1) as an adjunct to fusion in patients with the following indications: degenerative disc disease (DD), disc herniation (with myelopathy and/or radiculopathy), spondylolilsthesis, deformity (degenerative scoliosis or kyphosis), spinal stenosis, and failed previous fusion (pseudarthrosis). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have has at least six (6) months of non-operative treatment. Solar-MIM ALIF Spacers are to be filled with autograft bone and/or allogenic bone graft composed of cancellous and/or corticocancellous bone. These devices are intended to be used with supplemental fixation systems that have been cleared for use in the thoracolumbosacral spine (e.g., posterior pedicle screw and rod systems, anterior plate systems, anterior screw and rod systems). Hyperlordotic interbody devices (≥20° lordosis) must be used with at least anterior supplemental fixation.

| Type of Use (Select one or both, as applicable) | |
|------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| <div> <span> <span style="font-size: 16px;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) </span> </div> | <div> <span> <span style="font-size: 16px;">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) </span> </div> |

CONTINUE ON A SEPARATE PAGE IF NEEDED

{3}------------------------------------------------

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the logo for DeGen Medical. The logo features a stylized graphic of three curved lines emanating from a central point, with each line ending in a circle. The lines are blue, and the circles are a darker shade of blue. Below the graphic, the text "DeGen" is written in a bold, sans-serif font, also in blue. Below "DeGen", the word "Medical" is written in a smaller font.

# 510(k) Summary of Safety and Effectiveness

| Date | June 14, 2023 |
|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sponsor | DeGen Medical<br>1321-C North Cashua Drive<br>Florence, SC 29501<br>Phone [phone]<br>Fax [phone] |
| 510(k) Contact | Secure BioMed Evaluations<br>Justin Gracyalny, MSE<br>Linda Braddon, Ph.D.<br>7828 Hickory Flat Highway<br>Suite 120<br>Woodstock, GA 30188<br>770-837-2681<br>[e-mail] |
| Trade Name | Solar™ Lumbar Interbody Fusion System |
| Common Name | Intervertebral body fusion device |
| Code-<br>Classification | MAX, OVD, PHM<br>21 CFR 888.3080 : Class II |
| Primary<br>Predicate | K213935 Osseus Fusion Systems PISCES™-SA Standalone ALIF<br>Interbody System |
| Additional<br>Predicates | K191391, K222270 Globus Medical Inc. HEDRON™ Lumbar Spacers<br>K081849 Blackstone Medical Pillar SA PEEK Spacer System<br>K132790 Zimmer Spine InFix Anterior Lumbar System<br>K210090, K223418 DeGen Medical Impulse AM™ Interbody Fusion System |
| Device<br>Description | The Solar™ Lumbar Interbody Fusion System is a lumbar interbody fusion device for posterior and transforaminal lumbar fusion procedures. The Solar™ system includes various widths, depths, and heights. The Solar™ device is comprised of a single component that is additively manufactured. The superior and inferior endplates feature a porous surface to mitigate subsidence and expulsion. The standalone (Solar-S™), anterolateral (Solar-A™), and monolithic (Solar-M™) configurations feature an anterior face with threaded holes and slots to rigidly connect to an instrument for surgical insertion. Superior and inferior faces feature a central aperture to constrain bone graft. The DeGen Medical Solar™ spacers are additively manufactured from Puri-Ti™ unalloyed titanium. The Solar-S™ and Solar-A™ incorporate integrated fixation in the form of screws manufactured from Titanium-6AL-4V ELI Alloy per ASTM F136. The Solar-S™ Lumbar Interbody Spacer must be used with three (3) integrated screws and the spacer must have ≤20° of lordosis to be considered for standalone use. |
| Indications for<br>Use | Solar-ST™ (Standalone, With Integrated Fixation) and Solar-A™ (Non-<br>Standalone, With Integrated Fixation) |
| | The Solar-ST™ (Standalone) and Solar-A™ (Non-Standalone) are lumbar<br>interbody fusion devices intended for use in patients with degenerative disc<br>disease (DDD) at one or two contiguous levels of the lumbosacral spine<br>(L2-S1). DDD is defined as discogenic back pain with degeneration of the<br>disc confirmed by history and radiographic studies. In addition, these<br>patients may have up to Grade 1 spondylolisthesis or retrolisthesis at the<br>involved level(s). These patients should be skeletally mature and have had<br>at least six (6) months of non-operative treatment. Solar-ST™ and Solar-A™<br>ALIF Spacers are to be filled with autograft bone and/or allogenic bone<br>graft composed of cancellous and/or corticocancellous bone. |
| | • Solar-ST™ Used With Screws: |
| | When used with three (3) screws, interbody devices with a lordotic angle ≤<br>20° can be used as standalone interbody fusion devices at 1 or 2 contiguous<br>levels. |
| | Hyperlordotic interbody devices (>20° lordosis) used with screws, must<br>always be used with supplemental fixation, and may be used at 1 or 2 levels. |
| | • Solar-A™: |
| | These devices are intended to be used with supplemental fixation systems<br>that have been cleared for use in the lumbosacral spine (e.g., posterior<br>pedicle screw and rod systems, anterior plate systems, anterior screw and<br>rod systems). Hyperlordotic interbody devices (≥20° lordosis) must be used<br>with at least anterior supplemental fixation. |
| | Solar-M™ ALIF Spacers (Without Integrated Fixation) |
| | Solar-M™ ALIF Spacers are lumbar interbody fusion devices indicated at<br>one or more levels of the thoracic spine (T1-T12), thoracolumbar junction<br>(T12-L1), or lumbosacral spine (L1-S1) as an adjunct to fusion in patients<br>with the following indications: degenerative disc disease (DDD), disc<br>herniation (with myelopathy and/or radiculopathy), spondylolilsthesis,<br>deformity (degenerative scoliosis or kyphosis), spinal stenosis, and failed<br>previous fusion (pseudarthrosis). DDD is defined as discogenic back pain<br>with degeneration of the disc confirmed by history and radiographic<br>studies. These patients should be skeletally mature and have has at least six<br>(6) months of non-operative treatment. Solar-M™ ALIF Spacers are to be<br>filled with autograft bone and/or allogenic bone graft composed of<br>cancellous and/or corticocancellous bone. These devices are intended to be<br>used with supplemental fixation systems that have been cleared for use in<br>the thoracolumbosacral spine (e.g., posterior pedicle screw and rod<br>systems, anterior plate systems, anterior screw and rod systems). |
| Technological<br>Characteristics | Hyperlordotic interbody devices (≥20° lordosis) must be used with at least<br>anterior supplemental fixation.<br>There are no technological differences between the subject and predicate<br>device. The technological design features of the subject implants were<br>compared to the predicates in intended use, indications for use, design, function<br>and technology and it was demonstrated that they are substantially equivalent.<br>Non-clinical testing was performed to demonstrate the DeGen Medical<br>Solar™ Lumbar Interbody Fusion System is substantially equivalent to<br>other predicate devices in accordance with “Guidance for Industry and<br>FDA Staff, Guidance for Spinal System 510(k)s”, May 3, 2004 and Class<br>II Special Controls Guidance Document: Intervertebral Body Fusion<br>Device, June 12, 2007. |
| Performance<br>Testing | The following tests were performed to show equivalency:<br>● Static and dynamic compression testing per ASTM F2077<br>● Static and dynamic compression shear testing per ASTM F2077<br>● Subsidence testing via ASTM F2267<br>● Expulsion testing<br>● Wear debris characterization per ASTM F1877<br>The results of these studies show the subject DeGen Medical Solar™<br>Lumbar Interbody Fusion System is substantially equivalent to the predicate<br>device. |
| Conclusions | Based on the indications for use, technological characteristics, performance<br>testing, and comparison to the predicate device, the subject DeGen Medical<br>Solar™ Lumbar Interbody Fusion System is as safe and as effective as the<br>legally marketed predicate. |

{5}------------------------------------------------

Image /page/5/Picture/1 description: The image shows the logo for DeGen Medical. The logo features three blue circles connected by curved lines, resembling a stylized representation of medical technology or innovation. Below the graphic is the text "DeGen" in a bold, blue font, with the word "Medical" in a smaller, gray font underneath.

# 510(k) Summary of Safety and Effectiveness

{6}------------------------------------------------

Image /page/6/Picture/1 description: The image shows the logo for DeGen Medical. The logo features the company name in a bold, sans-serif font, with "DeGen" in a larger size and a darker color than "Medical." Above the text is a stylized graphic of three blue circles connected by curved lines, resembling a network or a flow of information. The overall design is modern and professional, suggesting a focus on technology and innovation in the medical field.

# 510(k) Summary of Safety and Effectiveness